Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
11,898 total articles
Matthew Paul Larson, Chief Risk Officer of Slide Insurance Holdings Inc. (NASDAQ:SLDE), sold 11,250 shares on March 3, 2026, for roughly $213,862 and concurrently exercised options on 11,250 shares at $0.79 per share. The moves were disclosed in a Form 4 filing and occur amid solid quarterly results and valuation metrics showing SLDE trading at a P…
Castle Biosciences Inc (NASDAQ:CSTL) Chief Financial Officer Frank Stokes sold 7,000 shares on March 3, 2026, in two tranches that generated roughly $192,073. Around the same time he sold additional shares to cover taxes and exercised options to acquire nearly 28,000 shares while receiving 48,367 restricted stock units. The activity coincides with …
LeonaBio, Inc. (NASDAQ: LONA) reported a modest insider sale by Chief Financial Officer Robert Renninger tied to taxes on vested restricted stock units, alongside disclosures that include option exercises and a remaining direct holding of 15,851 shares. The company is navigating a strategic pivot toward oncology with licensed global rights for laso…
Ryan Cohlhepp, President and COO of Bicara Therapeutics Inc. (BCAX), sold 17,392 shares on March 3, 2026, for about $315,892 and concurrently exercised options to acquire 12,892 shares. The transactions were carried out under a Rule 10b5-1 plan adopted February 12, 2025. Bicara has recently completed a large stock offering and received an analyst r…
Intuitive Surgical's SVP and head of manufacturing and supply chain, Brosius Mark, sold 3,658 shares of company stock in three transactions between March 3 and March 5, 2026, for a total of $1,815,061. The disposals were carried out under a Rule 10b5-1 trading plan set to expire February 14, 2027. Separately, the company reported robust fourth-quar…
Northern Trust Executive Vice President and Chief Financial Officer David W. Fox Jr. sold 3,255 shares on March 4, 2026, for $468,361. The transaction comes as the company reported stronger fourth-quarter 2025 results and multiple brokerages raised price targets. Fox's remaining direct and indirect holdings are detailed in a Form 4 filing.
Director Richard W. Fisher sold 16,345 shares of Warner Bros. Discovery (WBD) Series A common stock on March 3, 2026, generating about $462,726. The sale occurred as the stock has seen significant recent gains but is flagged as overvalued by InvestingPro. The transaction takes place against a backdrop of merger and deal activity, including Paramoun…
Will W Anthony, formerly president and CEO of CF Industries, sold 64,273 shares of common stock on March 3, 2026, in two transactions totaling about $7,009,894. After the sales Anthony retains direct ownership of 194,010 shares. The trades come while CF Industries shares trade near a 52-week high and after the company reported robust fourth-quarter…
SFS Holding Corp., an entity through which Mat Ishbia indirectly holds shares, sold 1,898,622 Class A shares of UWM Holdings Corp (NASDAQ: UWMC) across three transactions from March 3-5, 2026, generating roughly $7.9 million in proceeds. The trades were executed under a 10b5-1 plan adopted in September 2025. The sales occur against a backdrop of re…
NPEH, LLC, a 10% holder of NET Power Inc. (NYSE: NPWR), disposed of 100,000 Class A shares on March 3, 2026, receiving $204,250 for the stock sold at prices between $2.01 and $2.015. The transaction leaves NPEH with 400,000 directly held shares. NET Power has fallen roughly 70% over the past year and is trading near a 52-week low of $1.48; earnings…
Joseph Loscalzo, a member of Ionis Pharmaceuticals' board, sold 1,032 shares in early March 2026 for roughly $82,832 and simultaneously exercised options to acquire the same number of shares at $38.06. The transactions coincide with a flurry of regulatory and clinical activity at the biotech, including an FDA acceptance of a supplemental NDA for ol…
Ionis Pharmaceuticals director Joseph Klein III sold 21,332 shares on March 3, 2026 for roughly $1.7 million, with transaction prices between $79.174 and $80.818. He also exercised options to acquire 16,000 shares at strike prices of $40.05 and $42.88, valued at $652,120. After the trades, Klein owns 11,014 shares directly and his son holds 100 sha…
Shannon L. Devers, Executive Vice President and Chief Human Resources Officer at Ionis Pharmaceuticals, sold 20,006 shares on March 3, 2026, for about $1.59 million after exercising options to acquire the same number of shares. The company recently secured FDA Priority Review for olezarsen with a target action date of June 30, 2026, and will presen…
Allene M. Diaz, a director at Ionis Pharmaceuticals, sold $4.35 million of company stock on March 3, 2026, and exercised options to acquire an additional 40,321 shares. The transactions occurred under a Rule 10b5-1 plan and follow a period of strong one-year performance for the stock. Separately, Ionis has an FDA decision pending for olezarsen and …
C. Frank Bennett, Executive Vice President and Chief Scientific Officer of Ionis Pharmaceuticals (IONS), sold 85,089 shares on March 3, 2026, generating roughly $6.74 million in proceeds. Bennett also exercised options to acquire 65,089 shares at strike prices of $32.6 and $60.89, costing $3,497,530. After the transactions he directly holds 80,554 …
Warner Bros. Discovery Chief Executive David Zaslav completed a sale of 4,004,149 shares of Series A common stock on March 3, 2026, realizing $113,157,250 at a weighted average price of $28.26. The transaction leaves Zaslav with 7,200,627 directly held shares, while his spouse retains 153 indirect shares. The sale follows a 145% one-year return for…
Jesse Chen, a director at AXT Inc (NASDAQ: AXTI), disposed of 19,947 shares across March 4 and 5, 2026, generating $768,195 in proceeds. The stock has seen dramatic one-year gains, while the company has cut its fourth-quarter revenue guidance and analysts have adjusted ratings and price targets amid market and export-permit constraints.
GeneDx Holdings Corp. (NASDAQ: WGS) Chief Financial Officer Kevin Feeley sold 6,187 Class A shares on March 4, 2026, realizing $486,370. The sale, disclosed on a Form 4 filing, was executed to satisfy tax withholding tied to the vesting and settlement of a performance-based restricted stock unit award. The transactions occur alongside the company’s…
Dennis Howard, Charles Schwab's Chief Technology, Operations & Data Officer, sold 10,108 shares of common stock on March 3, 2026, in two transactions that together totaled about $956,227. The trades were carried out under a Rule 10b5-1 trading plan adopted November 25, 2025. Schwab shares trade near $95.41 and InvestingPro rates the stock as underv…
Alpha Metallurgical Resources Chief Financial Officer Joshua Todd Munsey sold 2,523 shares on March 4, 2026 for $183.24 per share, generating $462,314 in proceeds. The move comes as the stock has weakened and the company posted disappointing fourth-quarter 2025 results, prompting analyst caution and signaling persistent cost and margin pressures in…
Hercules Capital Chief Operating Officer Christian Follmann bought 5,000 shares of HTGC on March 4, 2026, spending $73,400. The purchase brings his direct holding to 150,135 shares. The transaction occurs amid the firm’s preliminary year-end NAV update, a loan amendment with Savara Inc., an analyst downgrade from Piper Sandler, and a critical short…
Ovintiv Inc. director Mayson Howard John sold 5,000 shares on March 3, 2026, realizing $261,950 at $52.39 per share. The transaction occurred while the stock traded close to its 52-week high following a six-month, 30% advance. The company also posted stronger-than-expected fourth-quarter 2025 earnings, while revenue matched forecasts.
Edmund Dunn, Principal Accounting Officer at Monte Rosa Therapeutics, sold 139 shares of common stock on March 4, 2026, in automatic transactions to satisfy tax withholding on vested restricted stock units. The sale, executed at $17.96 per share for a total of $2,496, leaves Dunn with 22,554 shares. The move comes amid rising GLUE share prices, rec…
Lara J. Kroll, SVP and Chief Accounting Officer at Chord Energy Corp (NYSE: CHRD), sold 5,000 shares on March 3, 2026, for roughly $568,300. The transaction occurred at an average price of $113.66 per share, with prices between $113.51 and $113.92. Separately, Chord reported fourth-quarter 2025 results with EPS of $1.28 versus an expected $1.40 and…
Cristen L. Kogl, Chief Legal Officer of Zebra Technologies Corp (NASDAQ: ZBRA), reported a series of transactions in early March including sales, acquisitions and the exercise of stock appreciation rights. The Form 4 filing outlines sales on March 4-5, purchases on March 3 and 5, and the exercise of SARs, leaving Kogl with 23,687 directly held shar…
